DOCSLIB.ORG

Relaxin-3/RXFP3 Networks: an Emerging Target for the Treatment of Depression and Other Neuropsychiatric Diseases?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Relaxin-3/RXFP3 Networks: an Emerging Target for the Treatment of Depression and Other Neuropsychiatric Diseases? Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases? Citation: Smith, Craig M., Walker, Andrew W., Hosken, Ihaia T., Chua, Berenice E., Zhang, Cary, Haidar, Mouna and Gundlach, Andrew L. 2014, Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases?, Frontiers in pharmacology, vol. 5, Article 46, pp. 1- 17. DOI: 10.3389/fphar.2014.00046 © 2014, The Authors Reproduced by Deakin University under the terms of the Creative Commons Attribution Licence Downloaded from DRO: http://hdl.handle.net/10536/DRO/DU:30093783 REVIEW ARTICLE published: 21 March 2014 doi: 10.3389/fphar.2014.00046 Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases? Craig M. Smith1,2 *, Andrew W. Walker 1,2 , IhaiaT. Hosken1,2 , Berenice E. Chua1, Cary Zhang1,2 , Mouna Haidar 1,2 and Andrew L. Gundlach1,2,3 * 1 Peptide Neurobiology Laboratory, Neuropeptides Division, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, VIC, Australia 2 Florey Department of Neuroscience and Mental Health, The University of Melbourne, VIC, Australia 3 Department of Anatomy and Neuroscience, The University of Melbourne, VIC, Australia Edited by: Animal and clinical studies of gene-environment interactions have helped elucidate the Laurence Lanfumey, Institut National mechanisms involved in the pathophysiology of several mental illnesses including anxiety, de la Santé et de la Recherche Médicale, France depression, and schizophrenia; and have led to the discovery of improved treatments. The study of neuropeptides and their receptors is a parallel frontier of neuropsychopharma- Reviewed by: Sara Morley-Fletcher, Centre National cology research and has revealed the involvement of several peptide systems in mental de la Recherche illnesses and identified novel targets for their treatment. Relaxin-3 is a newly discovered Scientifique-University Lille, France neuropeptide that binds, and activates the G-protein coupled receptor, RXFP3. Existing Pascal Bonaventure, Janssen Research & Development, LLC, USA anatomical and functional evidence suggests relaxin-3 is an arousal transmitter which is highly responsive to environmental stimuli, particularly neurogenic stressors, and in *Correspondence: Craig M. Smith and Andrew L. turn modulates behavioral responses to these stressors and alters key neural processes, Gundlach, Peptide Neurobiology including hippocampal theta rhythm and associated learning and memory. Here, we Laboratory, Neuropeptides Division, review published experimental data on relaxin-3/RXFP3 systems in rodents, and attempt The Florey Institute of Neuroscience and Mental Health, The University of to highlight aspects that are relevant and/or potentially translatable to the etiology and Melbourne, 30 Royal Parade, Parkville, treatment of major depression and anxiety. Evidence pertinent to autism spectrum and VIC 3052, Australia metabolism/eating disorders, or related psychiatric conditions, is also discussed. We also e-mail: craig.smith@florey.edu.au; nominate some key experimental studies required to better establish the therapeutic andrew.gundlach@florey.edu.au potential of this intriguing neuromodulatory signaling system, including an examination of the impact of RXFP3 agonists and antagonists on the overall activity of distinct or common neural substrates and circuitry that are identified as dysfunctional in these debilitating brain diseases. Keywords: relaxin-3, RXFP3, neuropeptide, arousal, stress, mood and depression, autism spectrum disorders, eating disorders INTRODUCTION key role in the neurophysiology of circuits associated with affec- It has now become widely accepted by neuroscientists and the tive behavior and cognition (Hoyer and Bartfai, 2012; Marder, clinical community that mental illness can arise from multiple 2012; van den Pol, 2012), and they can be both aberrant in sources and causes, including genetic mutations or epigenetic psychiatric pathology and targets for novel treatments (e.g., Dom- effects, and key environmental impacts during early develop- schke et al., 2011; Hoyer and Bartfai, 2012; Lin and Sibille, ment, and adolescence. A need for an ongoing reappraisal of 2013). how best to study and classify mental illness is also acknowl- Relaxin-3 is a highly conserved neuropeptide that is abun- edged, including the development of circuit-level frameworks dantly expressed in four small groups of largely γ-aminobutyric for understanding different modality deficits in depression (e.g., acid (GABA) projection neurons in mammalian brain (Bath- Nestler, 1998; Willner et al., 2013), autism spectrum disorders gate et al., 2002; Burazin et al., 2002; Tanaka et al., 2005), and (ASD; e.g., Haznedar et al., 2000; Markram and Markram, 2010; is involved in regulating aspects of physiological and behav- Yizhar et al., 2011b; Fan et al., 2012), and schizophrenia (e.g., ioral stress responses and the integration of sensory inputs (see Spencer et al., 2003; O’Donnell, 2011; Millan et al., 2012; Jiang Smith et al., 2011). Recent reviews have highlighted the putative et al., 2013). role of relaxin-3 in the control of feeding and the neuroen- Similarly, novel structural and molecular targets in brain that docrine axis (Tanaka, 2010; Ganella et al., 2012, 2013b). However, might underpin better treatments for the debilitating conditions existing neuroanatomical and functional evidence also suggests encompassed by the clinical spectrum of anxiety, major depres- the GABA/relaxin-3 system acts as a broad “arousal” network sion, and related psychiatric illnesses need to be identified and which is highly responsive to environmental stimuli (neurogenic explored. In this regard, it is clear that neuromodulatory sys- stressors) and modulates stress responses and other key behav- tems that utilize monoamine and peptide transmitters play a iors/neural processes. These effects are mediated via a variety www.frontiersin.org March 2014 | Volume 5 | Article 46 | 1 Smith et al. Relaxin-3/RXFP3 networks and neuropsychiatric disorders of mechanisms, such as influencing hippocampal theta rhythm been linked to pituitary adenylate cyclase-activating polypeptide and associated learning and memory, and via putative actions (PACAP) receptor-1 and corticotrophin-releasing factor (CRF) throughout the limbic system (Tanaka et al., 2005; Ma et al., receptor-2 signaling (Ressler et al., 2011; Lebow et al., 2012;see 2009a, 2013; Banerjee et al., 2010). Here, in the broader context also Dore et al., 2013); and neuropeptide Y (NPY) and CRF of the potential for neuropeptide-receptor systems as therapeu- appear to play a role not only in the underlying pathophysiol- tic drug targets (Hoyer and Bartfai, 2012), we review existing ogy of schizophrenia and depression, but as likely downstream experimental data on relaxin-3 and modulation of its receptor, mediators of the therapeutic effects following treatment with relaxin family peptide 3 receptor (RXFP3), in rodents and high- monoamine-targeting drugs (Arborelius et al., 1999; Ishida et al., light its relevance to the etiology of various neuropsychiatric 2007; Zorrilla and Koob, 2010; Nikisch et al., 2011). Not sur- disorders. prisingly, the antidepressant potential of drugs which directly target NPY and CRF signaling is currently under investiga- NEUROPEPTIDE-RECEPTOR SYSTEMS AS TARGETS FOR tion (Paez-Pereda et al., 2011), while drugs that target recep- TREATMENT OF NEUROPSYCHIATRIC DISORDERS tors for neurotrophic factors and other neuropeptides, such as Since the early discovery of “substance P”(von Euler and Gaddum, brain-derived neurotrophic factor (BDNF; Vithlani et al., 2013) 1931), a plethora of neuropeptide-receptor systems have been and neuropeptide S (NPS; Pape et al., 2010), offer consider- identified and characterized (see Hoyer and Bartfai, 2012). Neu- able promise as antidepressants and anxiolytics (Schmidt and ropeptides are commonly co-released with GABA/glutamate and Duman, 2010; McGonigle, 2011), in light of the effects of the monoamine transmitters, and generally signal through G-protein native peptides in relevant animal models of neurogenesis, and coupled receptors to modulate a broad range of neural processes neural structure and activity (Rotzinger et al., 2010; Pulga et al., and behaviors. The potential attractiveness of neuropeptide- 2012). receptor systems as therapeutic drug targets is enhanced by their However, from a translational viewpoint, over the last two high level of signaling specificity. For example, expression of neu- decades pharmaceutical and biotechnology groups have been ropeptides is often restricted to small populations of neurons attempting to target neuropeptide systems to treat various CNS within a small number of brain nuclei (e.g., orexin, MCH, and disorders and despite encouraging pre-clinical data, clinical stud- neuropeptide S; Xu et al., 2004; Sakurai, 2007; Saito and Nagasaki, ies investigating the antidepressant potential of neuropeptide 2008), and neuropeptides frequently bind to their receptors with receptor-targeting drugs have yielded mixed findings. For exam- high affinity and specificity due to their generally large allosteric ple, the neurokinin 1 (NK1) antagonist “aprepitant,” which is binding sites (Hoyer and Bartfai, 2012). Neuropeptides are also effective at treating nausea during chemotherapy (de Wit et al., often preferentially released under states of high neuronal firing 2004), was unsuccessful
Load more

Recommended publications
  • The Roles Played by Highly Truncated Splice Variants of G Protein-Coupled Receptors Helen Wise
    Wise Journal of Molecular Signaling 2012, 7:13 http://www.jmolecularsignaling.com/content/7/1/13 REVIEW Open Access The roles played by highly truncated splice variants of G protein-coupled receptors Helen Wise Abstract Alternative splicing of G protein-coupled receptor (GPCR) genes greatly increases the total number of receptor isoforms which may be expressed in a cell-dependent and time-dependent manner. This increased diversity of cell signaling options caused by the generation of splice variants is further enhanced by receptor dimerization. When alternative splicing generates highly truncated GPCRs with less than seven transmembrane (TM) domains, the predominant effect in vitro is that of a dominant-negative mutation associated with the retention of the wild-type receptor in the endoplasmic reticulum (ER). For constitutively active (agonist-independent) GPCRs, their attenuated expression on the cell surface, and consequent decreased basal activity due to the dominant-negative effect of truncated splice variants, has pathological consequences. Truncated splice variants may conversely offer protection from disease when expression of co-receptors for binding of infectious agents to cells is attenuated due to ER retention of the wild-type co-receptor. In this review, we will see that GPCRs retained in the ER can still be functionally active but also that highly truncated GPCRs may also be functionally active. Although rare, some truncated splice variants still bind ligand and activate cell signaling responses. More importantly, by forming heterodimers with full-length GPCRs, some truncated splice variants also provide opportunities to generate receptor complexes with unique pharmacological properties. So, instead of assuming that highly truncated GPCRs are associated with faulty transcription processes, it is time to reassess their potential benefit to the host organism.
    [Show full text]
  • Review Genetic Dissection of Mammalian Fertility Pathways Martin M
    fertility supplement review Genetic dissection of mammalian fertility pathways Martin M. Matzuk*†‡# and Dolores J. Lamb†§ Departments of *Pathology, †Molecular and Cellular Biology and ‡Molecular and Human Genetics, and §Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA #e-mail: [email protected] The world’s population is increasing at an alarming rate and is projected to reach nine billion by 2050. Despite this, 15% of couples world-wide remain childless because of infertility. Few genetic causes of infertility have been identified in humans; nevertheless, genetic aetiologies are thought to underlie many cases of idiopathic infertility. Mouse models with reproductive defects as a major phenotype are being rapidly created and discovered and now total over 200. These models are helping to define mechanisms of reproductive function, as well as identify potential new contracep- tive targets and genes involved in the pathophysiology of reproductive disorders. With this new information, men and women will continue to be confronted with difficult decisions on whether or not to use state-of-the-art technology and hormonal treatments to propagate their germline, despite the risks of transmitting mutant genes to their offspring. espite advances in assisted reproductive have been produced by spontaneous muta- Where it all begins technologies, infertility is a major health tions, fortuitous transgene integration, Reproductive development and physiology problem worldwide. Approximately 15% of retroviral infection of embryonic stem are evolutionarily conserved processes couples are unable to conceive within one cells, ethylnitrosurea (ENU) mutagenesis across eutherian mammalian species and year of unprotected intercourse. The fertil- and gene targeting technologies3,7,8.
    [Show full text]
  • The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: a Systematized Review
    International Journal of Molecular Sciences Review The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: A Systematized Review Hadrien Golay 1 , Simona Jurkovic Mlakar 1, Vid Mlakar 1, Tiago Nava 1,2 and Marc Ansari 1,2,* 1 Platform of Pediatric Onco-Hematology research (CANSEARCH Laboratory), Department of Pediatrics, Gynecology, and Obstetrics, University of Geneva, Bâtiment La Tulipe, Avenue de la Roseraie 64, 1205 Geneva, Switzerland 2 Department of Women-Children-Adolescents, Division of General Pediatrics, Pediatric Onco-Hematology Unit, Geneva University Hospitals (HUG), Avenue de la Roseraie 64, 1205 Geneva, Switzerland * Correspondence: [email protected] Received: 14 June 2019; Accepted: 7 August 2019; Published: 9 August 2019 Abstract: Hematopoietic stem cell transplantation (HSCT) remains the only curative treatment for several malignant and non-malignant diseases at the cost of serious treatment-related toxicities (TRTs). Recent research on extending the benefits of HSCT to more patients and indications has focused on limiting TRTs and improving immunological effects following proper mobilization and engraftment. Increasing numbers of studies report associations between HSCT outcomes and the expression or the manipulation of G protein-coupled receptors (GPCRs). This large family of cell surface receptors is involved in various human diseases. With ever-better knowledge of their crystal structures and signaling dynamics, GPCRs are already the targets for one third of the current therapeutic arsenal. The present paper assesses the current status of animal and human research on GPCRs in the context of selected HSCT outcomes via a systematized survey and analysis of the literature.
    [Show full text]
  • Relaxin Receptor RXFP1 and RXFP2 Expression in Ligament, Tendon, and Shoulder Joint Capsule of Rats
    ORIGINAL ARTICLE Rehabilitation & Sports Medicine http://dx.doi.org/10.3346/jkms.2016.31.6.983 • J Korean Med Sci 2016; 31: 983-988 Relaxin Receptor RXFP1 and RXFP2 Expression in Ligament, Tendon, and Shoulder Joint Capsule of Rats Jae Hyung Kim,1,2 Sang Kwang Lee,3 Numerous musculoskeletal disorders are caused by thickened ligament, tendon stiffness, or Seong Kyu Lee,4 Joo Heon Kim,5 fibrosis of joint capsule. Relaxin, a peptide hormone, can exert collagenolytic effect on and Michael Fredericson1 ligamentous and fibrotic tissues. We hypothesized that local injection of relaxin could be used to treat entrapment neuropathy and adhesive capsulitis. Because hormonal effect 1Division of Physical Medicine and Rehabilitation, Department of Orthopaedic Surgery, Stanford depends on the receptor of the hormone on the target cell, it is important to confirm the University, Stanford, CA, USA; 2Department of presence of such hormonal receptor at the target tissue before the hormone therapy is Physical Medicine & Rehabilitation, Eulji University initiated. The aim of this study was to determine whether there were relaxin receptors in Hospital and Eulji University School of Medicine, the ligament, tendon, and joint capsular tissues of rats and to identify the distribution of Daejeon, Korea; 3Eulji Medi-Bio Research Institute, Daejeon, Korea; 4Department of Biochemistry, Eulji relaxin receptors in these tissues. Transverse carpal ligaments (TCLs), inguinal ligaments, University School of Medicine, Daejeon, Korea; anterior cruciate ligaments (ACLs), Archilles tendons, and shoulder joint capsules were 5Department of Pathology, Eulji University School of obtained from male Wistar rats. Western blot analysis was used to identify relaxin receptor Medicine, Daejeon, Korea isoforms RXFP1 and RXFP2.
    [Show full text]
  • The Role of the Relaxin Receptor RXFP1 in Brain Cancer
    The role of the relaxin receptor RXFP1 in brain cancer By Usakorn Kunanuvat A Thesis submitted to the Faculty of Graduate Studies of The University of Manitoba in partial fulfilment for the requirements of the degree of MASTER OF SCIENCE Department of Human Anatomy and Cell Science University of Manitoba Winnipeg Copyright © 2012 by Usakorn Kunanuvat ABSTRACT Relaxin (RLN2) promotes cell migration/invasion, cell growth, and neoangiogenesis through binding to the relaxin receptor RXFP1 in many types of cancers. However, there have been no studies to determine the role of this system in brain tumors, especially in Glioblastoma Multiforme (GB), the most lethal primary brain tumor in adults. GB is a systemic brain disease and aggressively invades brain tissue. In this study, we have identified RXFP1 receptor, but not RLN2, in GB cell lines and primary GB cells from patients. RLN2 treatment resulted in a significant increase in migration of GB cell line and primary GB cells. To determine molecular mechanisms that facilitate RXFP1-mediated migration in GB cells, we employed a pseudopodia assay and 2D LC-MS/MS to investigate the protein composition at cell protrusions (pseudopodia) during GB cell migration. We also observed the expression of known mediators promoting tissue invasion upon RLN2 treatment. We identified PGRMC1, a candidate protein from 2D LC-MS/MS as a novel relaxin target protein in RXFP1-expressing brain tumor cells. RLN2 treatment also caused an increase in cathepsin (cath)-B and -L and enhanced production of as the small Rho-GTPases Rac1 and Cdc42 in GB cells. Collectively, these findings indicate that RXFP1-induced cell migration is mediated by the upregulation and intracellular actions of Rac1, Cdc42 and by cath-B and cath–L who serve as matrix modulating factors to facilitate brain tumor cells migration.
    [Show full text]
  • Altered Expression of RXFP1 Receptor Contributes to the Inefficacy of Relaxin-Based Anti-Fibrotic Treatments in Systemic Sclerosis C
    Altered expression of RXFP1 receptor contributes to the inefficacy of relaxin-based anti-fibrotic treatments in systemic sclerosis C. Corallo1, A.M. Pinto2, A. Renieri2, S. Cheleschi3, A. Fioravanti3, M. Cutolo4, S. Soldano4, R. Nuti1, N. Giordano1 1Scleroderma Unit, Department of ABSTRACT DcSSc-affected fibroblasts only, but not Medicine, Surgery and Neurosciences, Objective. Relaxin is a potent anti-fi- in LcSSc-unaffected and healthy ones. University of Siena; brotic hormone that has been tested to Conclusion. The absence/altered ex- 2Medical Genetics, Department of Medical ameliorate fibrosis in systemic sclerosis pression of relaxin receptor RXFP1 in Biotechnologies, University of Siena; 3Rheumatology Unit, Department of (SSc), but with controversial results. the affected fibroblasts of SSc patients Medicine, Surgery and Neurosciences, The aim of the study is to sequence re- could explain the inefficacy of relaxin- University of Siena; laxin receptor gene RXFP1 and to as- based anti-fibrotic treatments in the 4Research Laboratory and Academic sess its mRNA expression and protein disease. Division of Clinical Rheumatology, levels in the skin of SSc patients and Department of Internal Medicine, healthy subjects. Introduction University of Genova, Italy. Methods. Fibroblasts were isolated Systemic sclerosis (scleroderma, SSc) Claudio Corallo, PhD from unaffected/affected skin samples of is a rare, heterogeneous disease with a Anna Maria Pinto, MD, PhD (n=16) limited-cutaneous-SSc-(LcSSc) high associated mortality, characterised Alessandra Renieri, MD, PhD Sara Cheleschi, PhD and from affected ones of (n=4) diffuse- by progressive fibrosis of the skin and Antonella Fioravanti, MD cutaneous-SSc-(DcSSc) patients. Fibro- internal organs such as lungs, heart, Maurizio Cutolo, MD blasts from healthy subjects were used kidneys and gastrointestinal tract, cou- Stefano Soldano, PhD as controls.
    [Show full text]
  • In Vitro Pharmacological Characterization of RXFP3 Allosterism: an Example of Probe Dependency
    In Vitro Pharmacological Characterization of RXFP3 Allosterism: An Example of Probe Dependency Lily Alvarez-Jaimes, Steven W. Sutton*, Diane Nepomuceno, S. Timothy Motley, Miroslav Cik, Emily Stocking, James Shoblock, Pascal Bonaventure Janssen Pharmaceutical Companies of Johnson & Johnson, San Diego, California, United States of America Abstract Recent findings suggest that the relaxin-3 neural network may represent a new ascending arousal pathway able to modulate a range of neural circuits including those affecting circadian rhythm and sleep/wake states, spatial and emotional memory, motivation and reward, the response to stress, and feeding and metabolism. Therefore, the relaxin-3 receptor (RXFP3) is a potential therapeutic target for the treatment of various CNS diseases. Here we describe a novel selective RXFP3 receptor positive allosteric modulator (PAM), 3-[3,5-Bis(trifluoromethyl)phenyl]-1-(3,4-dichlorobenzyl)-1-[2-(5-methoxy-1H- indol-3-yl)ethyl]urea (135PAM1). Calcium mobilization and cAMP accumulation assays in cell lines expressing the cloned human RXFP3 receptor show the compound does not directly activate RXFP3 receptor but increases functional responses to amidated relaxin-3 or R3/I5, a chimera of the INSL5 A chain and the Relaxin-3 B chain. 135PAM1 increases calcium mobilization in the presence of relaxin-3NH2 and R3/I5NH2 with pEC50 values of 6.54 (6.46 to 6.64) and 6.07 (5.94 to 6.20), respectively. In the cAMP accumulation assay, 135PAM1 inhibits the CRE response to forskolin with a pIC50 of 6.12 (5.98 to 6.27) in the presence of a probe (10 nM) concentration of relaxin-3NH2.
    [Show full text]
  • Distribution, Physiology and Pharmacology of Relaxin-3/RXFP3 Systems in Brain
    British Journal of British Journal of Pharmacology (2017) 174 1034–1048 1034 BJP Pharmacology Themed Section: Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors REVIEW ARTICLE Distribution, physiology and pharmacology of relaxin-3/RXFP3 systems in brain Correspondence Andrew L. Gundlach, The Florey Institute of Neuroscience and Mental Health, 30 Royal Parade, Parkville, Victoria 3052, Australia. E-mail: andrew.gundlach@florey.edu.au Received 25 July 2016; Revised 12 October 2016; Accepted 17 October 2016 Sherie Ma1,2,CraigMSmith1,2,3,AnnaBlasiak4 and Andrew L Gundlach1,2,5 1The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia, 2Florey Department of Neuroscience and Mental Health, The University of Melbourne, Victoria Australia, 3School of Medicine, Deakin University, Geelong, Victoria, Australia, 4Department of Neurophysiology and Chronobiology, Institute of Zoology, Jagiellonian University, Krakow, Poland, and 5Department of Anatomy and Neuroscience, The University of Melbourne, Victoria, Australia Relaxin-3 is a member of a superfamily of structurally-related peptides that includes relaxin and insulin-like peptide hormones. Soon after the discovery of the relaxin-3 gene, relaxin-3 was identified as an abundant neuropeptide in brain with a distinctive topographical distribution within a small number of GABAergic neuron populations that is well conserved across species. Relaxin- 3 is thought to exert its biological actions through a single class-A GPCR – relaxin-family peptide receptor 3 (RXFP3). Class-A comprises GPCRs for relaxin-3 and insulin-like peptide-5 and other peptides such as orexin and the monoamine transmitters. The RXFP3 receptor is selectively activated by relaxin-3, whereas insulin-like peptide-5 is the cognate ligand for the related RXFP4 receptor.
    [Show full text]
  • Relaxin Receptor Antagonist AT-001 Synergizes with Docetaxel in Androgen-Independent Prostate Xenografts
    A Neschadim et al. AT-001 and docetaxel synergize 21:3 459–471 Research in cancer Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts Anton Neschadim, Laura B Pritzker1, Kenneth P H Pritzker1,2,3,4, Donald R Branch5,6,7,8, Alastair J S Summerlee9, John Trachtenberg10,11,12,13 and Joshua D Silvertown Armour Therapeutics, Inc., 124 Orchard View Boulevard, Toronto, Ontario, Canada 1Rna Diagnostics, Inc., 595 Bay Street, Suite 1204, Toronto, Ontario, Canada Departments of 2Laboratory Medicine and Pathobiology, and 3Surgery, University of Toronto, Toronto, Ontario, Canada 4Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada Departments of 5Medicine and 6Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada 7Centre for Innovation, Canadian Blood Services, Toronto, Ontario, Canada 8Division of Advanced Diagnostics – Infection and Immunity, Toronto General Research Institute (TGRI), Correspondence University Health Network, Toronto, Ontario, Canada should be addressed 9Department of Biomedical Sciences, University of Guelph, Guelph, Ontario, Canada to J D Silvertown 10Departments of Surgery and Medical Imaging, University of Toronto, Toronto, Ontario, Canada Email 11Division of Urology, Department of Surgical Oncology, 12Prostate Centre, Princess Margaret Hospital, and josh@armourtherapeutics. 13Ontario Cancer Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada com Endocrine-Related Cancer Abstract Androgen hormones and the androgen receptor (AR) pathway are the main targets of Key Words anti-hormonal therapies for prostate cancer. However, resistance inevitably develops to " prostate cancer treatments aimedattheAR pathway resulting in androgen-independent or hormone-refractory " anti-hormone therapy prostate cancer (HRPC). Therefore, there is a significant unmet need for new, non-androgen " angiogenesis anti-hormonal strategies for the management of prostate cancer.
    [Show full text]
  • The Effect of Estrogen on Tendon and Ligament Metabolism and Function
    Journal of Steroid Biochemistry and Molecular Biology 172 (2017) 106–116 Contents lists available at ScienceDirect Journal of Steroid Biochemistry and Molecular Biology journal homepage: www.elsevier.com/locate/jsbmb Review The effect of estrogen on tendon and ligament metabolism and function MARK ⁎ D.R. Leblanca, M. Schneiderb, P. Angeleb, G. Vollmerc, D. Dochevab,d, a Experimental Surgery and Regenerative Medicine, Department of Surgery, Ludwig-Maximilians-University Munich, Germany b Experimental Trauma Surgery, Department of Trauma Surgery, University Regensburg Medical Centre, Regensburg, Germany c Molecular Cell Physiology and Endocrinology, Institute of Zoology, Technical University, Dresden, Germany d Department of Medical Biology, Medical University-Plodiv, Plodiv, Bulgaria ARTICLE INFO ABSTRACT Keywords: Tendons and ligaments are crucial structures inside the musculoskeletal system. Still many issues in the treat- Estrogen ment of tendon diseases and injuries have yet not been resolved sufficiently. In particular, the role of estrogen- Musculoskeletal tissues like compound (ELC) in tendon biology has received until now little attention in modern research, despite ELC Tendons and ligaments being a well-studied and important factor in the physiology of other parts of the musculoskeletal system. In this Tendon cells review we attempt to summarize the available information on this topic and to determine many open questions in this field. 1. Introduction increase in the risk of cardio-vascular events, breast- and endometrial- cancer as well as thromboembolic events [7]. SERMs are a class of drugs For a long time estrogens have been known as a regulating factor of defined by their ability to target the same receptors as estrogen while the metabolism in many connective tissues, like bone [1], muscle [2] differing in their preference towards the various receptor-subtypes and and cartilage [3].
    [Show full text]
  • Session 7. Protein Functions in Cellular Signaling Lectures L7.1 L7.2
    Session 7. Protein Functions in Cellular Signaling Lectures L7.2 L7.1 Neutrophil extracellular traps (NETs) in autoinflammatory responses Molecular basis of macrophage Joanna Cichy activation by lipopolysaccharide Jagiellonian University, Faculty of Biochemistry, Biophysics & Katarzyna Kwiatkowska Biotechnology, Department of Immunology, Kraków, Poland e-mail: Joanna Cichy <[email protected]> Nnencki Institute of Experimental Biology, Department of Cell Biology, Warsaw, Poland e-mail: Katarzyna Kwiatkowska <[email protected]> Neutrophils also referred to as polymorphonuclear leuko- cytes (PMNs) form a part of the front line of host defense Lipopolysaccharide (LPS, endotoxin) is a component of against pathogens and are key component of tissue infil- the outer membrane of Gram-negative bacteria. LPS is an trates in autoinflammatory diseases such as systemic lupus archetypical pathogen-associated molecular pattern which erythematosus (SLE) and psoriasis. Activated neutrophils activates of one of Toll-like receptors (TLR), TLR4, of im- can eliminate microbes by the formation of neutrophil ex- mune cells. Upon infection it strongly stimulates production tracellular traps (NETs), extracellular decondensed chro- of pro-inflammatory mediators by macrophages. Excessive matin networks decorated with microbicidal agents. NETs host responses to LPS can lead to a systemic inflammatory were first reported to limit the growth and spread of mi- condition named septic shock. A relatively high incidence croorganisms through mechanically trapping pathogens and mortality of the disease drive studies on molecular and facilitating interaction of anti-microbial agents that are mechanisms of activation of cells by LPS. displayed on NETs with bacteria or fungi. More recently, In a typical scenario, activation of TLR4 is a multistep NETs were associated with tissue damage and autoinflam- process which begins in blood serum with binding of LPS matory diseases.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0237454 A1 Schutzer (43) Pub
    US 2013 0237454A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0237454 A1 Schutzer (43) Pub. Date: Sep. 12, 2013 (54) DIAGNOSTIC MARKERS FOR Publication Classification NEUROPSYCHATRC DISEASE (51) Int. Cl. (76) Inventor: Steven E. Schutzer, Water Mill, NY GOIN33/68 (2006.01) (US) (52) U.S. Cl. CPC .................................. G0IN33/6896 (2013.01) (21) Appl. No.: 13/697,417 USPC ............................................................ SO6/12 (22) PCT Filed: May 12, 2011 (57) ABSTRACT Biomarkers for the diagnosis of neuropsychiatric diseases are (86). PCT No.: PCT/US11?0O843 presented herein. In particular embodiments, biomarkers are S371 (c)(1), identified that are useful for diagnosing multiple Sclerosis, (2), (4) Date: May 23, 2013 chronic fatigue syndrome, or Neurologic Lyme disease. Also encompassed is a method for diagnosing a patient with a Related U.S. Application Data neuropsychiatric disease. Such as multiple Sclerosis, chronic AV fatigue syndrome, or Neurologic Lyme disease, by analyzing (60) Provisional application No. 61/395,354, filed on May biological samples isolated from the patient or the patient as 12, 2010. a whole to assess levels of the biomarkers described herein. -N- 1895 72% 63 735 8% 92% Patent Application Publication Sep. 12, 2013 US 2013/0237454 A1 Figure l US 2013/0237454 A1 Sep. 12, 2013 DAGNOSTIC MARKERS FOR tiple Sclerosis is more common in women than men and NEUROPSYCHATRC DISEASE generally begins between ages 20 and 40, but can develop at any age. Multiple Sclerosis is generally viewed as an autoim FIELD OF THE INVENTION mune syndrome directed against unidentified central nervous 0001. The present invention relates to identifying biologic tissue antigens.
    [Show full text]